and Sequence and Sequence Pair Selection Clause Samples

and Sequence and Sequence Pair Selection. During the portion of the Nomination Period prior to the […***…]6 anniversary of the Fifth Amendment Effective Date, Zymeworks shall not grant any Third Party a license under the […***…]7 to research, develop and commercialize Products, which license provides such Third Party with a […***…]8 or […***…]9 […***…]10 that would preclude GSK from […***…]11 or […***…]12. For clarity, the foregoing restriction shall expire on the […***…]13 anniversary of the Fifth Amendment Effective Date. From time to time during the portion of the Nomination Period following the […***…]14 anniversary of the Fifth Amendment Effective Date, GSK shall have the right to submit any number of Target(s) of interest to GSK to the […***…]15 as reasonably necessary to enable GSK to decide whether to nominate Sequences or Sequence Pairs Directed To such Target(s) as potential GSK Sequences or GSK Sequence Pairs, as the case may be; provided that submissions to the […***…]16 by or on behalf of GSK shall not occur so frequently in any given calendar month so as to be unduly burdensome to the […***…]17 or Zymeworks. GSK shall not be granted any rights or exclusivities with respect to any Targets that it submits to the […***…]18 for […***…]19. GSK shall, subject to Sections 3.4.3 and 3.4.6(a), have the right, during the Nomination Period, to select up to […***…]20 Sequences or Sequence Pairs to be GSK Sequences or GSK Sequence Pairs, as the case may be, in accordance with this Section 3.4, and the Licenses under Section 2.1 shall be granted to GSK solely with respect to such GSK Sequences or GSK Sequence Pairs, as applicable, GSK Antibodies generated and derived from such GSK Sequences or GSK Sequence Pairs, as the case may be, and Products incorporating such GSK Antibodies. In exchange for certain amounts as described in this Section 3.4 below, GSK shall have a right, during the Nomination Period, to nominate an additional […***…]21 Sequences or Sequence Pairs to be a GSK Sequence or GSK Sequence Pair, respectively, in accordance with this Section 3.4, for a total of up to […***…]22 GSK Sequences or GSK Sequence Pairs; provided that, in all events, no more than […***…]23 of such […***…]24 shall be Sequence Pairs (and the balance shall be Sequences). If GSK selects additional Sequences or 5 Competitive Information – Commercially Sensitive Terms. 6 Competitive Information – Commercially Sensitive Terms. 7 Competitive Information – Commercially Sensitive Terms. 8 Competitive Information – Comme...